Valproate (VPA)-associated hyperammonemic encephalopathy independent of elevated serum VPA levels: 21 cases in China from May 2000 to May 2012
| Autor: | Jihui Yue, Minfeng Cheng, Shenglin Wen, Hong Wang, Xiumei Tang |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty China Adolescent lcsh:RC435-571 Elevated serum Epilepsy lcsh:Psychiatry medicine Humans Hyperammonemia Bipolar disorder Adverse effect Aged Coma business.industry Mental Disorders Valproic Acid Middle Aged medicine.disease Discontinuation Psychiatry and Mental health Clinical Psychology Concomitant Anesthesia Child Preschool lipids (amino acids peptides and proteins) Female Neurotoxicity Syndromes medicine.symptom business Hyperammonemic encephalopathy |
| Zdroj: | Comprehensive Psychiatry, Vol 54, Iss 5, Pp 562-567 (2013) |
| ISSN: | 1532-8384 |
| Popis: | Valproate (VPA) is a medication that is widely used in the treatment of neurological and psychiatric disorders, such as epilepsy and bipolar disorder. Valproate-induced hyperammonemic encephalopathy (VHE) is a rare central nervous system adverse effect of this medication that is characterized by impaired consciousness, which can range from drowsiness to coma; increased seizure frequency; acute cognitive symptoms; and gastrointestinal symptoms. In this manuscript, we report a single case and also review previous cases of VHE (n = 20) in Chinese patients to identify risk factors for VHE. Increasing clinicians’ awareness of VHE during concomitant VPA therapy is of utmost importance. Serum ammonia level is a useful and important diagnostic test. The discontinuation of VPA is currently the mainstay of treatment for VHE. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect